VARILRIX Solution for Injection
Varicella Zoster Virus (live attenuated) Vaccine
1995.26 PFU
Abbott Laboratories GmbH
| Pack size | 1 Vial (0.5 ml) |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 166.60 AED |
Indications
VARILRIX Solution for Injection is used for:
Varicella-Zoster Virus Infection
Adult Dose
Subcuteneous
Varicella-Zoster Virus Infection
0.65 mL (entire content of vial ) injected SC into upper arm as single dose
Child Dose
Not indicated
Renal Dose
Administration
Contra Indications
A history of hypersensitivity to any component of the vaccine; individuals with blood dyscrasias, leukonia, lymphomas of any type, or other malignant neoplasma affecting the bone marrow or lymphatic systems; individuals receiving immunosuppressive therapy.
Precautions
Vaccination should be deferred to at least 5 months following blood or plasma transfusion, or administration of immunoglobulin or varicella-zoster immunoglobulin (VZIG).
Vaccination should be deferred in patients with a family history of congenital or hereditary immunodeficiency until the patient's own immune system has been evaluated.
Cases Requiring Careful Consideration Before Vaccination: The decision for vaccination is to be made carefully in the following categories, those having a history of seizures; those previously diagnosed with an immunodeficiency; those suffering from diseases accompanied by abnormal immune system function or those receiving immunosuppressive therapy; and those suspected of being allergic to any of the components.
Lactation: Unknown whether agent is excreted in breast milk; use with caution
Pregnancy-Lactation
Pregnancy
Contraindicated for use in pregnant women because the vaccine contains live, attenuated varicella-zoster virus, and it is known that wild-type varicella-zoster virus, if acquired during pregnancy, can cause congenital varicella syndrome (see Contraindications)
Lactation
Unknown whether varicella-zoster vaccine virus is excreted in human milk
For preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine
Interactions
Concurrent use may interfere with the immune response to certain live vaccines.
Adverse Effects
Side effects of Varicella Zoster Virus (live attenuated) Vaccine :
>10%
Injection-site erythema, Pain or tenderness, Pruritus, Swelling, Warmth
1-10%
Diarrhea (2%), Fever (2%), Flulike syndrome (2%), Upper respiratory tract infection (2%), Headache (1%), Rhinitis (1%), Skin disorder (1%), Weakness (1%)
<1%
Arthralgia, Hypersensitivity, Injection-site reactions
Mechanism of Action
Conveys active immunity by stimulating production of endogenously produced antibodies
Note
VARILRIX 1995.26 PFU Solution for Injection manufactured by Abbott Laboratories GmbH. Its generic name is Varicella Zoster Virus (live attenuated) Vaccine. VARILRIX is availble in Saudi Arabia.
Farmaco SA drug index information on VARILRIX Solution for Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.